Search
Filters
total: 2762
filtered: 120
-
Catalog
Chosen catalog filters
Search results for: LYMPHOID LEUKEMIAS (C42.1)
-
Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia
PublicationAcute leukemia (AL) with a lineage switch (LS) is associated with poor prognosis. The predisposing factors of LS are unknown, apart from KMT2A rearrangements that have been reported to be associated with LS. Herein, we present two cases and review all 104 published cases to identify risk factors for LS. Most of the patients (75.5%) experienced a switch from the lymphoid phenotype to the myeloid phenotype. Eighteen patients (17.0%)...
-
Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results
Publication -
A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia
Publication -
Potential impact of parents' lifestyle on the occurrence of leukemia in their children
Publication -
Region-Specific Methylation Profiling in Acute Myeloid Leukemia
Publication -
Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma
Publication -
Innate lymphoid cells type 2 – emerging immune regulators of obesity and atherosclerosis
Publication -
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group
Publication -
The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia
Publication -
Deep Data Analysis of a Large Microarray Collection for Leukemia Biomarker Identification
Publication -
Identification of two novel mutations in human acute myeloid leukemia cases
Publication -
Postibrutinib outcomes in patients with mantle cell lymphoma
Publication -
Use of acalabrutinib in patients with mantle cell lymphoma
Publication -
Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG)
Publication -
Apoptosis of human leukemia cells induced by imidazoacridinone derivative C-1311 (Symadex)
PublicationPraca dotyczy różnej wrażliwości komórek białaczek ludzkich do ulegania apoptozie pod wpływem pochodnej imidazoakrydonu C-1311, co jest zgodne z aktywnością cytotoksyczną tego związku (EC90) wobec badanych komórek.
-
Comparison of the ability to induce apoptosis by acridine derivatives in solid tumor and leukemia cells
PublicationW pracy wykazano różną wrażliwość komórek nowotworowych do ulegania apoptozie pod wpływem pochodnych akrydyny.
-
The potential interaction of environmental pollutants and circadian rhythm regulations that may cause leukemia
PublicationTumor suppressor genes are highly affected during the development of leukemia, including circadian clock genes. Circadian rhythms constitute an evolutionary molecular machinery involving many genes, such as BMAL1, CLOCK, CRY1, CRY2, PER1, PER2, REV-ERBa, and RORA, for tracking time and optimizing daily life during day-night cycles and seasonal changes. For circulating blood cells many of these genes coordinate their proliferation,...
-
C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells
PublicationGen ABCG2 charakteryzuje polimorficzność pozycji C341, która jest związana ze znacznym obniżeniem ekspresji tego genu i zdolności do transportu przez błonę komórkową. W pracy wykazaliśmy, że komórki raka płuc, które nabyły oporności na związek C-1305, zmieniły fenotyp z heterozygotycznego w odniesieniu do genu ABCG2 i wykazują amplifikację jedynie allelu C341 genu oraz zwiększoną zawartość mRNA i zmutowanego białka pompy ABCG2...
-
Gemcitabine-Based Treatment in Poor Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience
Publication -
Substance P – a potent risk factor in childhood lymphoblastic leukaemia
Publication -
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Publication -
Induction of apoptosis by triazoloacridinone derivative - C-1533 in HL60 and MOLT4 human leukemia cells.
PublicationPrzeprowadzone badania miały na celu określenie zdolności triazoloakrydonu C-1533 do indukcji śmierci komórek nowotworowych MOLT4 i HL60 na drodze apoptozy. Badanie zjawiska apoptozy przeprowadzono z wykorzystaniem techniki cytofluorymetrii przepływowej, mikroskopii fluorescencyjnej i elektroforezy agarozowej. Badania wykazały, że zarówno w komórkach MOLT4 jak i HL60, spadek mitochondrialnego potencjału błonowego oraz translokacja...
-
Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab‑associated anaphylaxis
Publication -
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†
Publication -
Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group
Publication -
Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers
Publication -
Novel Method of Identifying DNA Methylation Fingerprint of Acute Myeloid Leukaemia
Publication -
Atypical course of varicella-zoster infection in a child with acute lymphoblastic leukaemia
Publication -
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Publication -
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Publication -
Lactoferrin B Combined with Antibiotics Exhibits Leukemic Selectivity and Antimicrobial Activity
Publication -
Lactoferricin B Combined with Antibiotics Exhibits Leukemic Selectivity and Antimicrobial Activity
Publication -
Lactoferricin B Combined with Antibiotics Exhibits Leukemic Selectivity and Antimicrobial Activity
Publication -
Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311
PublicationWykazano, że pochodna imidazoakrydonu C-1311 indukuje zahamowanie progresji komórek MOLT4 w fazie G2M cyklu życiowego. Podwyższona ekspresja fosfoepitopu MPM-2 przy jednoczesnym zaniku ufosforylowanej formy Tyr15-cdc2 wskazywała, iż komórki początkowo zablokowane w fazie G2 przechodziły do mitozy. Jednocześnie na skutek nieprawidłowego przebiegu mitozy komórki ulegały katastrofie mitotycznej. Analiza biochenicznych markerów apoptozy...
-
How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?
Publication -
NRF2-related transcriptomic alterations as a long-term effect of doxorubicin treatment for childhood acute lymphoblastic leukemia
Publication -
Transcriptomic and proteomic analysis of mouse radiation-induced acute myeloid leukaemia (AML)
Publication -
St. Jude Total Therapy studies from I to XVII for childhood acute lymphoblastic leukemia: a brief review
Publication -
Label-free testing strategy to evaluate packed red blood cell quality before transfusion to leukemia patients
Publication -
Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305
PublicationWykazaliśmy, że pochodna triazoloakrydonu C-1305 w stężeniach biologicznie istotnych indukuje blok cyklu komórkowego w fazie G2/M i apoptozę w komórkach białaczek ludzkich MOLT4 i HL60. Zjawisko apoptozy zostało określone na podstawie charakterystycznych zmian morfologicznych jak i biochemicznych tj. fragmentacji DNA, aktywacji kaspazy 3, cięcia PARP, spadku potencjału mitochondrialnego i ATP oraz eksternalizacji fosfatydyloseryny.
-
Dual-Activity Fluoroquinolone-Transportan 10 Conjugates offer alternative Leukemia therapy during Hematopoietic Cell Transplantation
PublicationHematopoietic cell transplantation (HCT) is often considered a last resort leukemia treatment, fraught with limited success due to microbial infections, a leading cause of mortality in leukemia patients. To address this critical issue, we explored a novel approach by synthesizing antileukemic agents containing antibacterial substances. This innovative strategy involves conjugating fluoroquinolone antibiotics, such as ciprofloxacin...
-
A 10-Year-old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir
Publication -
Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream.
PublicationIn patients with leukemia, the portal(s) and reasons for the persistence of an Escherichia coli recurrent bacteremia remain unclear. Adult Hematology Clinic (AHC) databases at the State Clinical Hospital in Gdańsk were reviewed to evaluate the frequency of E. coli bacteremia between 2002 and 2005. Blood and bowel E. coli strains were obtained and the genetic relatedness of the strains was analyzed. The rate of E. coli bacteremia...
-
CD105 and placental growth factor – Potent prognostic factors in childhood acute lymphoblastic leukaemia
Publication -
Independent Mechanisms Lead to Genomic Instability in Hodgkin Lymphoma: Microsatellite or Chromosomal Instability
Publication -
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Publication -
Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells
PublicationDrugs targeting receptor tyrosine kinase FLT3 are of particular interest since activating FLT3-internal tandem duplication (ITD) mutations abundantly occur in fatal acute myeloid leukemias (AMLs). Imidazoacridinone C-1311, a DNA-reactive inhibitor of topoisomerase II, has been previously shown to be a potent and selective inhibitor of recombinant FLT3. Here, we expand those findings by studying its effect on leukemia cells with...
-
Antitumor triazoloacridinone C-1305 as a potent FLT3 tyrosine kinase inhibitor in human acute myeloid leukemia (AML) cells.
PublicationJednym z defektów molekularnych u pacjentów z ostrą białaczką szpikową (AML) jest konstytutywna aktywacja receptoroweej kinazy tyrozynowj FLT3.Najczęstszą mutacją genu kodującego FLT3 jest wewnętrzna tandemowa duplikacja ITD we fragmencie okołobłonowym receptora. W pracy zbadano, czy przeciwnowotworowy triazoloakrydon C-1305 może być inhibitorem kinazy tyrozynowej FLT3. Badania przeprowadzono na dwóch liniach komórkowych białaczek...
-
Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials
Publication -
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
Publication